Abstract
Alzheimer’s disease (AD) is a major concern, impacting millions of people around the globe and creating significant clinical and economic challenges. While factors like age and genetics, particularly the APOE-ε4 gene, are key players in risk assessments, there are also modifiable factors—like vascular disease, diabetes, head injuries, and substance use—that greatly affect when and if someone develops clinical AD. Among the substances that could potentially lead to neurodegenerative issues, amphetamine-type stimulants—both prescription medications and illegal methamphetamine—deserve immediate attention. Their widespread use, whether for medical purposes or recreationally, along with their strong psychostimulant effects and increasing evidence of lasting brain damage, calls for a thorough investigation into how stimulant use might raise the risk of AD or speed up its neurological decline.
References
Shukla M, Vincent B. The multi-faceted impact of methamphetamine on Alzheimer’s disease: From a triggering role to a possible therapeutic use. Ageing research reviews. 2020;60:101062.
Maes M, Altufaili MF, Alhaideri AF, Moustafa SR, Stoyanova K, Niu M, et al. The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress. Current Topics in Medicinal Chemistry. 2024;24(20):1816-1828.
Alabed S, Zhou H, Sariyer IK, Chang SL. Meta-analysis of methamphetamine modulation on amyloid precursor protein through HMGB1 in Alzheimer’s disease. International Journal of Molecular Sciences. 2021;22(9):4781.
Gao Z-x, Zhang C, Lu J-c, Zhao X, Qiu H, Wang H-j. Pathological methamphetamine exposure triggers the accumulation of neuropathic protein amyloid-β by inhibiting UCHL1. Neurotoxicology. 2021;86:19-25.
Zhu Y, Wang X, Hu M, Yang T, Xu H, Kang X, et al. Targeting Aβ and p‐Tau Clearance in Methamphetamine‐Induced Alzheimer’s Disease‐Like Pathology: Roles of Syntaxin 17 in Autophagic Degradation in Primary Hippocampal Neurons. Oxidative Medicine and Cellular Longevity. 2022;2022(1):3344569.
Panmak P, Nopparat C, Permpoonpattana K, Namyen J, Govitrapong P. Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus. Neurochemistry international. 2021;148:105121.
Chen G, Wei X, Xu X, Yu G, Yong Z, Su R, et al. Methamphetamine inhibits long-term memory acquisition and synaptic plasticity by evoking endoplasmic reticulum stress. Frontiers in neuroscience. 2021;14:630713.
Wang HA, Liang HJ, Ernst TM, Nakama H, Cunningham E, Chang L. Independent and combined effects of methamphetamine use disorders and APOEε4 allele on cognitive performance and brain morphometry. Addiction. 2023;118(12):2384-2396.
Tzeng NS, Chien WC, Chung CH, Chang HA, Kao YC, Liu YP. Association between amphetamine‐related disorders and dementia‐a nationwide cohort study in Taiwan. Annals of Clinical and Translational Neurology. 2020;7(8):1284-1295.
Mizoguchi H, Yamada K. Methamphetamine use causes cognitive impairment and altered decision-making. Neurochemistry international. 2019;124:106-113.
Dean AC, Morales AM, Hellemann G, London ED. Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology. 2018;43(8):1745-1752.
Abood MT, Mohammed MT. Methamphetamine-Induced Cognitive Impairment: Evaluation of amyloid beta 40 and phosphorylated tau protein 217 in male Users. Behavioural Brain Research. 2025:115701.
Ranjkeshzadeh H, Sepahi S, Zare-Zardini H, Taghavizadeh Yazdi ME, Ghorani-Azam A, Jafari A. A review of drug abuse, misuse, and related laboratory challenges. Current Drug Safety. 2024;19(4):417-430.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Adel Ghorani-Azam (Author)